Dosage for Ipamorelin and CJC-1295: What Research Protocols Actually Use

Most research protocols that combine these two peptides use 100-300 mcg of ipamorelin plus 100 mcg of CJC-1295 without DAC per injection, taken one to three times daily. The long-acting version, CJC-1295 with DAC, is dosed completely differently, usually 1-2 mg once or twice a week. Those figures come from research literature and community reports rather than approved prescribing guidance, because neither peptide is FDA-approved for human use in the United States.

Typical Ipamorelin and CJC-1295 Dosing at a Glance

Dose depends almost entirely on which CJC-1295 you are working with. The two versions share a name but behave like different compounds.

The most commonly cited cjc-1295 ipamorelin dosage is 100 mcg of each peptide drawn into the same syringe and injected once or twice a day. Raising the ipamorelin portion to 200 mcg is also common, while pushing past 300 mcg per injection does not appear to add benefit and is more often linked to side effects.

CJC-1295 With DAC vs. Without DAC: Two Very Different Doses

CJC-1295 without DAC is frequently labeled Mod GRF 1-29. It clears the body in roughly 30 minutes, which is why it is paired with a short-acting secretagogue like ipamorelin and dosed multiple times per day.

The cjc 1295 without dac and ipamorelin dosage is the combination most beginners encounter: 100 mcg of each peptide, one to three times daily, usually capped at a total of 300 mcg of ipamorelin per day.

By contrast, the cjc 1295 dac and ipamorelin dosage looks nothing like a daily regimen. Because the DAC version binds to albumin and stays active for roughly six to eight days, it is typically dosed at 1-2 mg per week, often split into two injections of 1 mg, while ipamorelin is still used at 100-200 mcg two or three times daily alongside it.

Confusing the two forms is the single most common dosing error reported by users. Taking 1 mg of CJC-1295 without DAC would be an enormous overdose relative to research norms, and taking 100 mcg of the DAC version would be far too little to have a meaningful effect.

Where Ipamorelin Fits in the Stack

Ipamorelin is a selective growth hormone secretagogue, meaning it signals the pituitary to release growth hormone without strongly raising cortisol or prolactin the way older peptides do. CJC-1295 amplifies that same signal by extending the growth hormone pulse.

Research protocols generally treat ipamorelin as the flexible half of the pair:

• Low end: 100 mcg per injection, often used by first-time researchers or smaller body weights.
• Mid range: 150-200 mcg, the most frequently reported dose.
• High end: 300 mcg, generally reserved for once-daily nighttime dosing rather than repeated injections.

Timing, Frequency, and Cycle Length

• Timing: Most protocols schedule injections before bed, since the largest natural growth hormone pulse happens during deep sleep. A morning or post-workout dose is sometimes added.
• Frequency: One to three injections per day. More frequent dosing is not automatically better and increases the chance of side effects.
• Cycle length: 8-12 weeks on, followed by a break of four weeks or more.
• Days off: Some users follow a five-days-on, two-days-off pattern in an attempt to reduce desensitization.
• Empty stomach: Because insulin blunts growth hormone release, most protocols call for dosing at least 30 minutes before or two hours after eating.

None of these schedules are validated in large human trials. They are conventions that spread through research forums, not conclusions from controlled studies.

What Is CJC-1295 Ipamorelin Used For?

People often ask what is cjc 1295 ipamorelin used for, and the honest answer is that research interest centers on growth hormone output, body composition, recovery, sleep quality, and skin. Human data on the combination is thin, and most of what circulates online is anecdotal.

Claims about cjc 1295 ipamorelin for weight loss deserve extra caution. Growth hormone secretagogues may shift body composition slightly in some studies, but they are not weight loss drugs, and no regulator has approved this combination for fat loss. Marketing promises about rapid fat loss should be treated with skepticism.

Men and women are generally given the same dose in research settings. Sex does not appear to change the published dosing ranges, even though bodybuilding communities discuss the stack far more openly than clinical literature does.

Side Effects, Safety, and Legal Status

Reported side effects from growth hormone secretagogues include:

• Injection-site redness, irritation, and bruising
• Headache, flushing, or lightheadedness shortly after dosing
• Increased hunger, water retention, and tingling in the hands
• Fatigue or disrupted sleep at higher doses

Ipamorelin is considered the most selective of the common growth hormone secretagogues, which is why it is often described as having a gentler side effect profile. That does not make the combination risk-free, and long-term human safety data is essentially absent.

Neither ipamorelin nor CJC-1295 is FDA-approved for human use in the United States. Both are sold as research chemicals, and buying or possessing them for personal use sits in a legal gray area that varies by state. Anyone considering these peptides should speak with a licensed healthcare professional instead of relying on forum dosing charts.